Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen. Liu KJ, Li HR, Tan QQ, Jiang T, et al. Lung Cancer 2024;195:107933.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Liu KJ, Li HR, Tan QQ, Jiang T, et al. Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen. Lung Cancer 2024;195:107933.
PMID: 39191079